Cynvenio’s LiquidBiopsy® Platform on Display at Molecular Med Tri-Con 2017 - 
February 19-24, 2017 - San Francisco, California

Company will demo its LiquidBiopsy system for rare cell isolation and molecular characterization

WESTLAKE VILLAGE, CA – February 10, 2017 – Cynvenio Biosystems, Inc. today announced that its LiquidBiopsy rare cell isolation platform will be featured at Molecular Med Tri-Con 2017 - booth 128. The event takes place February 19-24, 2017 at The Moscone North Convention Center, 747 Howard Street San Francisco, CA 94103 ( ).

For NGS applications the LiquidBiopsy platform delivers an end-to-end, blood-to-sequence workflow that runs faster and more precisely on less than 10ng of DNA input material than approaches from competing vendors. When used with Cynvenio’s specialty NGS gene panels and cloud-based bioinformatics the LiquidBiopsy workflow can cut processing times by 60%-80%. This means that labs can operate at higher scale, with better quality control, and more profitably by eliminating traditional sequencing bottlenecks. 

For molecular characterization via FISH or IHC the LiquidBiopsy platform delivers target cells that can be stained, enumerated and microscopically characterized using standard fluorescent or immunohistochemical protocols. Alternatively, the product of the LiquidBiopsy platform is compatible with FISH and single cell applications. 

The LiquidBiopsy system is widely deployed in support of research applications in oncology and non-invasive prenatal testing.

About Cynvenio Biosystems, Inc.

Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients.  Among the company’s breakthroughs are its line of ClearID® tests for greatly improved cancer detection andmonitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California (Los Angeles). For more information, please visit and

LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.